Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 19 July 2018

Indication(s)

Inhixa is indicated in adults for:
• Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.
• Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE likely to require thrombolytic therapy or surgery.
• Prevention of thrombus formation in extra corporeal circulation during haemodialysis.
• Acute coronary syndrome:
- Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.
- Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI).

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Fibrinogen Deficiency in Bleeding

Fibrinogen Deficiency in Bleeding

Fibrinogen is important for blood clot formation and breakdown. It is the first coagulant factor to be reduced to critical levels during massive trauma, cardiac surgery and postpartum haemorrhage that involve excessive bleeding. Persistent fibrinogen deficiency can lead to bleeding complications and an increased risk in mortality. This learning zone looks at both congenital and acquired fibrinogen deficiencies including indications and techniques for diagnosis, trigger level for treatment and treatment options.

Load more

Related Content

Journal articles

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Background: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.

Added 1 year ago

Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.

Background: Adherence to oral anticoagulant (OAC) agents is important for patients with nonvalvular atrial fibrillation (NVAF) to prevent potentially severe adverse events.

Added 1 year ago

Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium.

Aim: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome...

Added 1 year ago

Rivaroxaban in patients with a recent acute coronary syndrome.

Background: Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve...

Added 1 year ago

ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison.

Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations.

Added 3 days ago

Load more

View all 13535 Journal articles items
Guidelines

Prevention and management of venous thromboembolism

The guideline identifies adult patient groups at risk of venous thromboembolism and describes the available methods of prophylaxis, with general recommendations about efficacy, safety, and how they should be used.

Added 8 years ago

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

VTE is a condition in which a blood clot (thrombus) forms in a vein. It most commonly occurs in the...

Added 9 years ago

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R

The scope of this focused update of the 2014 AF Guideline includes revisions to the section on anticoagulation (because of the approval of new medications and thromboembolism protection devices), revisions to the section...

Added 8 days ago

Guideline on aspects of cancer-related venous thrombosis

This guideline reviews the indication for warfarin, duration or treatment for patients with a PE and/or lower limb DVT, the initiation of treatment, the management of peri-operative anticoagulation, the management of patients who are bleeding or...

Added 3 years ago

Antithrombotics: indications and management

This guideline provides recommendations based on current evidence for best practice in the management of adult patients on antithrombotic therapy.

Added 6 years ago

Load more

View all 1465 Guidelines items

More information

Category Value
Agency product number EMEA/H/C/004264
Orphan designation No
Date First Approved 15-09-2016
Type Medicinal product subject to medical prescription
Marketing authorisation holder Techdow Europe AB